When clinical endpoints are subjective, image-based or complex to assess or the study is geographically broad, researchers of new drugs and devices may find it difficult to demonstrate acceptable safety results to regulatory authorities.

To meet this requirement, trial sponsors and Contract Research Organizations (CROs) are turning to Clinical Endpoint Committees (CEC) for independent event adjudication as the most efficient process to help reduce costs, increase quality, and eliminate clinical bias. Traditional manual, paper-based approaches to CEC management place significant time, cost, and resource burdens on organizations – and are prone to errors, bias and regulatory issues.

As with many other areas of clinical research, innovative new technologies are helping to remove these barriers and drive significant gains in cutting costs, improving data quality, speeding time to market and smoothing regulatory approval. Today’s web-based adjudication systems offer advantages that inefficient paper-based processes cannot.

Download this white paper today to learn how innovative new technologies are helping to remove these barriers and offer advantages that inefficient, paper-based processes cannot to drive significant gains in: